A Clinical Study Of 22.5 mg. La-2550: A New Subcutaneous Depot Delivery System For Leuprolide Acetate For The Treatment Of Prostate Cancer-Reference-Cited by-同舟云学术

A Clinical Study Of 22.5 mg. La-2550: A New Subcutaneous Depot Delivery System For Leuprolide Acetate For The Treatment Of Prostate Cancer

Published:2002-09 Issue:3 Volume:168 Page:1199-1203
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Chu Franklin M.¹,Jayson Maury¹,Dineen Martin K.¹,Perez Ramon¹,Harkaway Richard¹,Tyler Robert C.¹

Affiliation:

1. From the San Bernardino Urological Associates, San Bernardino, California, Medical and Clinical Research Associates, Bay Shore, New York, Atlantic Urological Associates, Daytona Beach and Urology Health Center, New Port Richey, Florida, Albert Einstein Medical Center, Philadelphia, Pennsylvania, and Atrix Laboratories, Fort Collins, Colorado

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference20 articles.

1. Studies on prostate cancer; effect of castration, estrogen of androgen injection on serum phosphatases in metastatic carcinoma of the prostate;Huggins;Cancer Res,1941

2. Comparison of leuprolide diethylstilbestrol for stage D2 adenocarcinoma of prostate;Sharifi;Urology,1985

3. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists;Tolis;Proc Natl Acad Sci USA,1982

4. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer;Sharifi;Clin Ther,1996

5. Comparison of LH-RH analogue 1-month depot 3-month depot by their hormone levels pharmacokinetic profile in patients with advanced prostate cancer;Tunn;Urol Int,1998

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-acting injectable PLGA/PLA depots for leuprolide acetate: successful translation from bench to clinic;Drug Delivery and Translational Research;2022-08-17

2. Leveraging the therapeutic, biological, and self-assembling potential of peptides for the treatment of viral infections;Journal of Controlled Release;2022-08

3. The industrial design, translation, and development strategies for long-acting peptide delivery;Expert Opinion on Drug Delivery;2022-07-21

4. Advanced delivery of leuprorelin acetate for the treatment of prostatic cancer;Expert Review of Anticancer Therapy;2022-06-03

5. ELIGANT: a Phase 4, interventional, safety study of leuprorelin acetate (ELIGARD®) in Asian men with prostate cancer;Translational Andrology and Urology;2022-02